Haleon

Subdued performance in North America has resulted in a guidance downgrade

31/07/25 -"Haleon’s H1 profitability surpassed expectations. Sales growth was primarily driven by Oral Health, Therapeutic Skin Health, Pain Relief, and VMS, though it was partially offset by weaknesses ..."

PDF page sample
Pages
56
Language
English
Published on
31/07/25
Download
You may also be interested by these reports :
01/08/25
L’Oréal posted mixed H1 25 results, with the top-line slightly below expectations but stronger than expected profitability. North America ...
31/07/25
Haleon’s H1 profitability surpassed expectations. Sales growth was primarily driven by Oral Health, Therapeutic Skin Health, Pain Relief, and VMS, ...
31/07/25
Bic posted a mixed H1 FY25, with EBIT and EPS slightly ahead of expectations, but FCF missing significantly at -€14m. Sales declined 2.7% yoy in Q2, ...
31/07/25
The company exceeded expectations with organic growth of 3.4% vs anticipated 3.3%, bolstering market confidence in its strength and future ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO